Lipid profiling reveals different therapeutic effects of metformin and glipizide in patients with type 2 diabetes and coronary artery disease

Diabetes Care

Volumn 37, Issue 10, 2014, Pages 2804-2812

  Zhang, Yifei ^a   Hu, Chunxiu ^b   Hong, Jie ^a   Zeng, Jun ^b   Lai, Shenghan ^c   Lv, Ankang ^a   Su, Qing ^a   Dong, Yan ^a   Zhou, Zhiguang ^d   Tang, Weili ^d   Zhao, Jiajun ^e   Cui, Lianqun ^e   Zou, Dajin ^f   Wang, Dawang ^g   Li, Hong ^h   Liu, Chao ⁱ   Wu, Guoting ^j   Shen, Jie ^k   Zhu, Dalong ^l   Wang, Weiqing ^a   Shen, Weifeng ^a   Ning, Guang ^a   Xu, Guowang ^b   more..

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e SHANDONG UNIVERSITY   (China)

^f SECOND MILITARY MEDICAL UNIVERSITY   (China)

^g WENZHOU MEDICAL UNIVERSITY   (China)

^h ZHEJIANG UNIVERSITY   (China)

ⁱ THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^j TONGJI UNIVERSITY   (China)

^k FIRST MILITARY MEDICAL UNIVERSITY   (China)

^l THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER; GLIPIZIDE; METFORMIN; SPHINGOMYELIN; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; LIPID;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; METABOLOME; METABOLOMICS; MIDDLE AGED;

AGED; BLOOD GLUCOSE; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; FEMALE; GLIPIZIDE; HUMANS; LIPIDS; MALE; METABOLOME; METABOLOMICS; METFORMIN; MIDDLE AGED;

EID: 84908215156     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0090     Document Type: Article

References (38)

1. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 1998;21:1138-1145.
2. Bertoni AG, Krop JS, Anderson GF, Brancati FL. Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care 2002;25:471-475.
3. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303.
4. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adultonset diabetes. II. Mortality results. Diabetes 1970;19(Suppl.):789-830.
5. The University Group Diabetes Program. The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of pheniformin therapy. Diabetes 1975;24(Suppl. 1):65-184.
6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
7. Hong J, Zhang Y, Lai S, et al.; SPREAD-DIMCAD Investigators. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013;36:1304-1311.
8. Rhee EP, Cheng S, Larson MG, et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest 2011;121:1402-1411.
9. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:448-453.
10. Rhee EP, Gerszten RE. Metabolomics and cardiovascular biomarker discovery. Clin Chem 2012;58:139-147.
11. Fernandez C, Sandin M, Sampaio JL, et al. Plasma lipid composition and risk of developing cardiovascular disease. PLoS ONE 2013;8: e71846.
12. Heather LC, Wang X, West JA, Griffin JL. A practical guide to meta bolomic profiling as a discovery tool for human heart disease. J Mol Cell Cardiol 2013;55:2-11.
13. Bernini P, Bertini I, Luchinat C, Tenori L, Tognaccini A. The cardiovascular risk of healthy individuals studied by NMR meta bonomics of plasma samples. J Proteome Res 2011;10: 4983-4992.
14. Cheng S, Rhee EP, Larson MG, et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation 2012;125:2222-2231.
15. McCormack SE, Shaham O, McCarthy MA, et al. Circulating branched-chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents. Pediatr Obes 2013;8:52-61.
16. Würtz P, Soininen P, Kangas AJ, et al. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care 2013;36:648-655.
17. Floegel A, Stefan N, Yu Z, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 2013;62:639-648.
18. Wang-Sattler R, Yu Z, Herder C, et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol 2012;8:615.
19. Ferrannini E, Natali A, Camastra S, et al. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes 2013;62: 1730-1737.
20. Gall WE, Beebe K, Lawton KA, et al.; RISC Study Group. alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS ONE 2010;5:e10883.
21. Juraschek SP, Steffes MW, Miller ER 3rd, Selvin E. Alternative markers of hyperglycemia and risk of diabetes. Diabetes Care 2012;35: 2265-2270.
22. Hu C, van Dommelen J, van der Heijden R, et al. RPLC-ion-trap-FTMS method for lipid profiling of plasma: method validation and application to p53 mutant mouse model. J Proteome Res 2008;7:4982-4991.
23. Wang C, Kong H, Guan Y, et al. Plasma phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis. Anal Chem 2005;77:4108-4116.
24. Keun HC, Ebbels TM, Bollard ME, et al. Geometric trajectory analysis of metabolic responses to toxicity can define treatment specific profiles. Chem Res Toxicol 2004;17: 579-587.
25. Lund SS, Gong Y. Comment on Hong et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes care 2013;36:1304-1311. Diabetes Care 2014; 37:e19-e20.
26. Hong J, Zhang Y, Lai S, Ning G. Response to comment on Hong et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes care 2013;36:1304-1311. Diabetes Care 2014;37:e21.
27. Brown AS. Lipid management in patients with diabetes mellitus. Am J Cardiol 2005;96: 26E-32E.
28. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A 1988;85: 2805-2809.
29. Schmitz G, Ruebsaamen K. Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis 2010;208:10- 18.
30. Quehenberger O, Dennis EA. The human plasma lipidome. N Engl J Med 2011;365: 1812-1823.
31. Zhang J, Tu K, Xu Y, et al. Sphingomyelin in erythrocytemembranes increases the total cholesterol content of erythrocyte membranes in patients with acute coronary syndrome. Coron Artery Dis 2013;24:361-367.
32. Mäkinen VP, Tynkkynen T, Soininen P, et al. Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study). Metabolomics 2012;8:369-375.
33. Yeboah J, McNamara C, Jiang XC, et al. Association of plasma sphingomyelin levels and incident coronary heart disease events in an adult population: Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30:628-633.
34. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472:57-63.
35. Graessler J, Schwudke D, Schwarz PE, Herzog R, Shevchenko A, Bornstein SR. Topdown lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PLoS ONE 2009;4:e6261.
36. Gaikwad NW. Ultra performance liquid chromatography-tandem mass spectrometry method for profiling of steroid metabolome in human tissue. Anal Chem 2013;85:4951-4960.
37. Weir JM, Wong G, Barlow CK, et al. Plasma lipid profiling in a large population-based cohort. J Lipid Res 2013;54:2898-2908.
38. Schwab U, Seppänen-Laakso T, Yetukuri L, et al.; GENOBIN Study Group. Triacylglycerol fatty acid composition in diet-induced weight loss in subjects with abnormal glucose metabolism- The GENOBIN study. PLoS ONE 2008;3:e2630.